- Home
- PSNL vs ONCY Comparison
PSNL vs ONCY Comparison
Compare PSNL & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- ONCY
- Stock Information
- Founded
- PSNL 2011
- ONCY 1998
- Country
- PSNL United States
- ONCY Canada
- Employees
- PSNL N/A
- ONCY N/A
- Industry
- PSNL Medical Specialities
- ONCY Pharmaceuticals and Biotechnology
- Sector
- PSNL Health Care
- ONCY Health Care
- Exchange
- PSNL Nasdaq
- ONCY Nasdaq
- Market Cap
- PSNL 321.1M
- ONCY 103.8M
- IPO Year
- PSNL 2019
- ONCY 1999
- Fundamental
- Price
- PSNL $5.19
- ONCY $1.19
- Analyst Decision
- PSNL Strong Buy
- ONCY Strong Buy
- Analyst Count
- PSNL 4
- ONCY 2
- Target Price
- PSNL $6.81
- ONCY $4.00
- AVG Volume (30 Days)
- PSNL 439.4K
- ONCY 903.7K
- Earning Date
- PSNL 11-06-2024
- ONCY 11-05-2024
- Dividend Yield
- PSNL N/A
- ONCY N/A
- EPS Growth
- PSNL N/A
- ONCY N/A
- EPS
- PSNL N/A
- ONCY N/A
- Revenue
- PSNL $80,027,000.00
- ONCY N/A
- Revenue This Year
- PSNL $10.85
- ONCY N/A
- Revenue Next Year
- PSNL $8.77
- ONCY N/A
- P/E Ratio
- PSNL N/A
- ONCY N/A
- Revenue Growth
- PSNL 19.20
- ONCY N/A
- 52 Week Low
- PSNL $0.89
- ONCY $0.84
- 52 Week High
- PSNL $7.20
- ONCY $1.80
- Technical
- Relative Strength Index (RSI)
- PSNL 56.29
- ONCY 52.51
- Support Level
- PSNL $4.54
- ONCY $1.17
- Resistance Level
- PSNL $5.35
- ONCY $1.28
- Average True Range (ATR)
- PSNL 0.30
- ONCY 0.09
- MACD
- PSNL 0.05
- ONCY -0.01
- Stochastic Oscillator
- PSNL 84.71
- ONCY 28.00
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.